Blogs Contact Us Login
1
DasKloster 1000-01
Pulmonary Arterial Hypertension (PAH)
Patent Applied
Ready for licensing
Phase II
2
DasKloster 1000–04
Acute Respiratory Distress Syndrome (ARDS/ALI)
Patent Applied
Orphan Drug Designation granted
in EU & US
Phase I
3
Das Kloster 0141-01
Acute Respiratory Distress Syndrome (ARDS/ALI)
Patent Applied
Ready for licensing
Phase I
4
DasKloster 1001-01
Idiopathic Pulmonary Fibrosis (IPF)
Patent Applied
Orphan Drug Designation granted in EU
Phase I
5
DasKloster 0112-01
Sarcoidosis
Patent Applied
Ready for licensing
Phase II
6
DasKloster 0210-01
Chronic Beryllium Disease (CBD)
Patent Applied
Orphan Drug Designation granted in US
Ready for licensing
Fase I
7
DasKloster 0014-01
Hepatitis B Virus induced Hepatocellular Carcinoma
Patent Applied
Ready for licensing
Pre-clinical
8
DasKloster 0249-01
Drug Resistant Tuberculosis
Patent Applied
Ready for licensing
In collaboration with Pharmarare SA
Pre-clinical
9
73 In Development
Target not disclosed
Development Stages

Pipeline

How does Mondobiotech work

Learn More
Acute Respiratory Distress Syndrome (ARDS/ALI)
DasKloster 1000–04
Asbestosis
DasKloster 0039-01
Chronic Beryllium Disease (CBD)
DasKloster 0210-01
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
DasKloster 0247-01
Drug Resistant Tuberculosis
DasKloster 0249-01
Hepatitis B Virus induced Hepatocellular Carcinoma
DasKloster 0014-01
Idiopathic Pulmonary Fibrosis (IPF)
DasKloster 1001-01
Lymphangioleiomyomatosis (LAM)
DasKloster 0080-01
Methicillin-Resistant Staphylococcus Aureus in Cystic Fibrosis
DasKloster 0138–01
Pseudomonas Aeruginosa in Cystic Fibrosis
DasKloster 0274-01
Pulmonary Arterial Hypertension (PAH)
DasKloster 1000-01
Sarcoidosis
DasKloster 1000–02
Scleroderma
DasKloster 0501-01